Trial Profile
A retrospective study evaluating pembrolizumab, pomalidomide and dexamethasone combination therapy in pre-treated pomalidomide exposed patients with relapsed or refractory multiple myeloma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 24 Jan 2017
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary) ; Pomalidomide (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Therapeutic Use
- 24 Jan 2017 New trial record
- 06 Dec 2016 Results presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.